Xactly Corp

Belkins
Xactly delivers a scalable, enterprise platform for planning and incenting sales organizations, including sales quota and territory planning, incentive compensation management, and predictive analytics. Using this powerful sales performance management (SPM) portfolio, customers mitigate risk, accelerate sales performance, and increase business agility. Combined with Xactly Insights™-- the industry’s only empirical big data platform, Xactly empowers companies with real-time compensation insights and benchmarking data that maximize the bottom line. With an open, standards-based architecture, Xactly seamlessly integrates within an enterprise’s existing infrastructure, with the ability to work with any ERP, CRM, or HCM application, while meeting the highest enterprise standards in security, reliability, and privacy.

C-Suite On Deck

Erik Charles, Vice President and Solutions Evangelist at Xactly Corporation is an accomplished professional with over two decades of experience in Marketing, Consulting, and Product Evangelization. Erik focuses on helping companies drive expansion and growth by better aligning posi...

Events

Related News

MEDICAL

FRESH FROM RAISING $200M, BRITISH BIOTECH WITH AN HQ IN RALEIGH MULLS TARGETING COVID-19

Verona Pharma | November 19, 2020

news image

A British clinical-stage biotech firm with U.S. base camp in Raleigh is investigating the alternative of repurposing its leading drug candidate to treat COVID-19 patients. Flush with $200 million after a July raise, the London-based Verona Pharma is now making large walks with its "first-in-class" drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD). Now, against the backdrop of a pandemic, it’s pushing ahead with a pilot clinic...

Read More

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

news image

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More

INDUSTRIAL IMPACT

GEOVAX ANNOUNCES $10 MILLION PRIVATE PLACEMENT

GeoVax, Inc. | January 15, 2022

news image

GeoVax Labs, Inc. a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock ...

Read More

ARCTIC VISION ANNOUNCES US$32MN IN SERIES A TO EXPAND INNOVATIVE PRODUCT PORTFOLIO IN OPHTHALMOLOGY

Arctic Vision | July 15, 2020

news image

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.&...

Read More
news image

MEDICAL

FRESH FROM RAISING $200M, BRITISH BIOTECH WITH AN HQ IN RALEIGH MULLS TARGETING COVID-19

Verona Pharma | November 19, 2020

A British clinical-stage biotech firm with U.S. base camp in Raleigh is investigating the alternative of repurposing its leading drug candidate to treat COVID-19 patients. Flush with $200 million after a July raise, the London-based Verona Pharma is now making large walks with its "first-in-class" drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD). Now, against the backdrop of a pandemic, it’s pushing ahead with a pilot clinic...

Read More
news image

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More
news image

INDUSTRIAL IMPACT

GEOVAX ANNOUNCES $10 MILLION PRIVATE PLACEMENT

GeoVax, Inc. | January 15, 2022

GeoVax Labs, Inc. a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock ...

Read More
news image

ARCTIC VISION ANNOUNCES US$32MN IN SERIES A TO EXPAND INNOVATIVE PRODUCT PORTFOLIO IN OPHTHALMOLOGY

Arctic Vision | July 15, 2020

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.&...

Read More

Resources

Events

C-Suite On Deck

Erik Charles, Vice President and Solutions Evangelist at Xactly Corporation is an accomplished professional with over two decades of experience in Marketing, Consulting, and Product Evangelization. Erik focuses on helping companies drive expansion and growth by better aligning posi...